Toshio Fujino

1.5k total citations · 1 hit paper
54 papers, 975 citations indexed

About

Toshio Fujino is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Toshio Fujino has authored 54 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Toshio Fujino's work include Lung Cancer Treatments and Mutations (33 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Toshio Fujino is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Toshio Fujino collaborates with scholars based in Japan, United States and Austria. Toshio Fujino's co-authors include Tetsuya Mitsudomi, Kenichi Suda, Shuta Ohara, T. Koga, Masato Chiba, Toshiki Takemoto, Masaya Nishino, Masaki Shimoji, Junichi Soh and Akira Hamada and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer and Cancer Research.

In The Last Decade

Toshio Fujino

48 papers receiving 947 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Toshio Fujino Japan	16	563	420	402	142	105	54	975
V. Damiano Italy	15	568 1.0×	796 1.9×	502 1.2×	181 1.3×	78 0.7×	34	1.3k
Takamitsu Onitsuka Japan	14	616 1.1×	635 1.5×	538 1.3×	212 1.5×	107 1.0×	28	1.2k
Jia Luo United States	15	458 0.8×	528 1.3×	328 0.8×	288 2.0×	108 1.0×	64	1.0k
Guoshuang Shen China	14	356 0.6×	538 1.3×	298 0.7×	219 1.5×	73 0.7×	61	1000
Yasuro Fukuyama Japan	17	592 1.1×	447 1.1×	728 1.8×	180 1.3×	57 0.5×	41	1.4k
A-P Meert Belgium	7	799 1.4×	732 1.7×	548 1.4×	266 1.9×	68 0.6×	17	1.3k
Pierre‐Alexandre Just France	17	281 0.5×	269 0.6×	415 1.0×	222 1.6×	125 1.2×	45	1.1k
Andrea Mancuso Italy	14	299 0.5×	432 1.0×	202 0.5×	166 1.2×	121 1.2×	35	726
Jaymes Holland United States	14	299 0.5×	259 0.6×	294 0.7×	143 1.0×	66 0.6×	25	769
Haruyoshi Tanaka Japan	20	314 0.6×	352 0.8×	496 1.2×	179 1.3×	79 0.8×	52	947

Countries citing papers authored by Toshio Fujino

Since Specialization

Citations

This map shows the geographic impact of Toshio Fujino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshio Fujino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshio Fujino more than expected).

Fields of papers citing papers by Toshio Fujino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshio Fujino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshio Fujino. The network helps show where Toshio Fujino may publish in the future.

Co-authorship network of co-authors of Toshio Fujino

This figure shows the co-authorship network connecting the top 25 collaborators of Toshio Fujino. A scholar is included among the top collaborators of Toshio Fujino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshio Fujino. Toshio Fujino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suda, Kenichi, Akira Hamada, Toshio Fujino, et al.. (2025). Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study. Cells. 14(17). 1386–1386.

Hamada, Akira, Kenichi Suda, Masaya Nishino, et al.. (2023). Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. Journal of Thoracic Oncology. 19(1). 71–79. 9 indexed citations

Lim, Sun Min, Toshio Fujino, Dong‐Wan Kim, et al.. (2023). BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(16). 3004–3016. 48 indexed citations

Ohara, Shuta, Kenichi Suda, Toshio Fujino, et al.. (2021). Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. Lung Cancer. 154. 84–91. 10 indexed citations

Nishino, Masaya, Kenichi Suda, T. Koga, et al.. (2021). Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance. Thoracic Cancer. 12(10). 1511–1516. 25 indexed citations

Takemoto, Toshiki, Junichi Soh, Shuta Ohara, et al.. (2021). The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. Surgery Today. 51(9). 1480–1487. 7 indexed citations

Ohara, Shuta, Kenichi Suda, Kenji Tomizawa, et al.. (2020). Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer. Surgery Today. 50(11). 1427–1433. 15 indexed citations

Fujino, Toshio, Kenichi Suda, & Tetsuya Mitsudomi. (2020). Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Emerging Drugs. 25(3). 229–249. 33 indexed citations

Ohara, Shuta, Kenji Tomizawa, Shigeki Shimizu, et al.. (2019). Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. SHILAP Revista de lepidopterología. 5(1). 105–105.

10.

Fujino, Toshio, Yoshihisa Kobayashi, Kenichi Suda, et al.. (2019). Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. Journal of Thoracic Oncology. 14(10). 1753–1765. 114 indexed citations

11.

Koga, T., Kenichi Suda, Masaya Nishino, et al.. (2019). P2.03-20 Potent in Vitro Activity of Tarloxotinib for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance. Journal of Thoracic Oncology. 14(10). S690–S691. 4 indexed citations

12.

Koga, T., Yoshihisa Kobayashi, Kenji Tomizawa, et al.. (2018). Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer. 126. 72–79. 52 indexed citations

13.

Fujino, Toshio, Kenichi Suda, Yoshihisa Kobayashi, et al.. (2018). P1.13-41 In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping. Journal of Thoracic Oncology. 13(10). S598–S598. 1 indexed citations

14.

Tomizawa, Kenji, Shigeki Shimizu, Shuta Ohara, et al.. (2017). Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer. 112. 57–61. 11 indexed citations

15.

Fujino, Toshio, et al.. (1991). [Arrhythmogenesis of changes in cellular ionic environments: ischemia-induced increase in intracellular resistance and slow conduction].. PubMed. 39(8). 793–800. 1 indexed citations

16.

Mitsudo, Kazuaki, Toshio Fujino, Keiji Matsunaga, et al.. (1989). [Coronary arteriographic findings in the patients with atrial septal defect and pulmonary hypertension (ASD + PH)--compression of left main coronary artery by pulmonary trunk].. PubMed. 37(6). 649–55. 31 indexed citations

17.

Mitsudo, Kazuaki, et al.. (1985). CORONARY ARTERIOGRAPHIC FINDINGS IN THE PATIENTS WITH ATRIAL SEPTAL DEFECT WITH PULMONARY HYPERTENSION (ASD+PH) : COMPRESSION OF LEFT MAIN TRUNK BY PULMONARY TRUNK : Ischemic Heart Disease (V) : FREE COMMUNICATIONS (V) : PROCEEDINGS OF THE 49th ANNUAL SCIENTIFIC MEETING OF THE JAPANESE CIRCULATION SOCIETY. Japanese Circulation Journal-english Edition. 49(8). 872–873. 2 indexed citations

18.

Mitsudo, Kazuaki, Toshio Fujino, Osamu Doi, et al.. (1983). CORONARY ANGIOGRAPHIC RISK FACTORS OF MECHANICAL FAILURE IN ACUTE MYOCARDIAL INFARCTION : PROCEEDINGS OF THE 47th ANNUAL SCIENTIFIC MEETING OF THE JAPANESE CIRCULATION SOCIETY : Ischemic Heart Disease (III). Japanese Circulation Journal-english Edition. 47(8). 900. 2 indexed citations

19.

Fujino, Toshio. (1981). The Role of Estrogen in the Regulation of Corpus Luteum Function in the Midpregnant Rat. 28(1). 35–40. 1 indexed citations

20.

Fujino, Toshio. (1962). The electric activity of the biliary system. 11(3).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact